HR
RARE icon

Howe & Rusling’s Ultragenyx Pharmaceutical RARE Stock Holding History

Howe & Rusling’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219K Buy
+6,554
New +$163K 0.01% 299
2022
Q4 		– Sell
-298
Closed -$12K – 860
2022
Q3 		$12K Hold
298
– – ﹤0.01% 511
2022
Q2 		$18K Buy
298
+158
+113% +$9.72K ﹤0.01% 438
2022
Q1 		$10K Buy
+140
New +$9.74K ﹤0.01% 529
2016
Q3 		– Sell
-10
Closed – – 1105
2016
Q2 		$0 Hold
10
– – ﹤0.01% 1034
2016
Q1 		$1K Hold
10
– – ﹤0.01% 954
2015
Q4 		$1K Buy
10
+3
+43% +$300 ﹤0.01% 930
2015
Q3 		$1K Buy
+7
New +$801 ﹤0.01% 946

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Howe & Rusling's RARE Position: Q2 2026 in Review

Howe & Rusling opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 6,554 shares worth $219K. The stake represents 0.01% of the portfolio and ranks #299 among its holdings. This is a return to the name: Howe & Rusling previously reported a position in RARE as recently as Q3 2022.

Howe & Rusling first reported a position in RARE in Q3 2015 and has held it in 8 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Howe & Rusling held 6,554 shares of Ultragenyx Pharmaceutical worth $219K as of Q2 2026.
  • Ultragenyx Pharmaceutical was a new Howe & Rusling position in Q2 2026.
  • Ultragenyx Pharmaceutical made up 0.01% of Howe & Rusling's portfolio in Q2 2026, its #299 holding.
  • Howe & Rusling first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and has held it in 8 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Howe & Rusling's 13F filing for Q2 2026, filed 10 Aug 2026.